Advancement Of Sickle Cell Disease Drug Development By Product Type And Applications/End Industries, 2017

Researchmoz added Most up-to-date research on "Advancement Of Sickle Cell Disease Drug Development By Product Type And Applications/End Industries, 2017" to its huge collection of research reports.

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. There are a total of 62 products in development for this indication, by 45 companies and nine academic institutions. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394151

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/sickle-cell-disease-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Survey Report: Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

Researchmoz added Most up-to-date research on "Survey Report: Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018" to its huge collection of research reports.

This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued projects.

NAFLD and NASH represent considerable burdens for healthcare systems, particularly in developed countries where NAFLD is the most common liver disorder.

NAFLD is strongly related to insulin resistance and is therefore often treated by therapeutics originally intended for use in diabetes mellitus. Up to 80% of obese people have NAFLD, which is usually asymptomatic or mildly symptomatic.

NASH is a severe form of NAFLD. It presents as a swelled or inflamed liver and may result in cirrhosis and consequent liver failure. As populations age the incidence of NASH is likely to rise and become a major healthcare concern for western systems.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1701729

Scope

- Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse TOC @ https://www.researchmoz.us/non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash-drug-development-pipeline-review-2018-report.html/toc

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Gastrointestinal Report Coverage 9
2.2 Non-Alcoholic Steatohepatitis (NASH) - Overview 9
2.3 Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 9
3 Therapeutics Development 10
3.1 Non-Alcoholic Steatohepatitis (NASH) 10
3.2 Non Alcoholic Fatty Liver Disease (NAFLD) 29
4 Therapeutics Assessment 37
4.1 Non-Alcoholic Steatohepatitis (NASH) 37
4.2 Non Alcoholic Fatty Liver Disease (NAFLD) 48
5 Companies Involved in Therapeutics Development 58
5.1 Non-Alcoholic Steatohepatitis (NASH) 58
5.2 Non Alcoholic Fatty Liver Disease (NAFLD) 103
6 Dormant Projects 124
6.1 Non-Alcoholic Steatohepatitis (NASH) 124
6.2 Non Alcoholic Fatty Liver Disease (NAFLD) 127

Rising Concern About The Use Of Fungal Foot Infections Drug Development Pipeline Review, 2018

Researchmoz added Most up-to-date research on "Rising Concern About The Use Of Fungal Foot Infections Drug Development Pipeline Review, 2018" to its huge collection of research reports.

This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athletes foot (Tinea pedis), and key players active within these indications.

Both of these indications are fungal infections primarily affecting the feet. Onychomycosis affects the nails, whereas athletes foot affects the skin under the feet and between the toes. Common symptoms include discomfort, itchiness, and - in the case of onychomycosis - discoloured and disfigured nails. Combined, these infections affect around 25% of the adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology. There are a total of 25 products in development for both indications, by 24 companies.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1701730

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse TOC @ https://www.researchmoz.us/fungal-foot-infections-drug-development-pipeline-review-2018-report.html/toc

Table of Content

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Fungal Foot Infections Report Coverage 7
2.2 Onychomycosis (Tinea Unguium) - Overview 7
2.3 Tinea pedis (Athlete Foot) - Overview 7
3 Therapeutics Development 8
3.1 Onychomycosis (Tinea Unguium) 8
3.2 Tinea pedis (Athlete Foot) 12
4 Therapeutics Assessment 15
4.1 Onychomycosis (Tinea Unguium) 15
4.2 Tinea pedis (Athlete Foot) 21
5 Companies Involved in Therapeutics Development 26
5.1 Onychomycosis (Tinea Unguium) 26
5.2 Tinea pedis (Athlete Foot) 32
6 Dormant Projects 36
6.1 Onychomycosis (Tinea Unguium) 36
6.2 Tinea pedis (Athlete Foot) 38
7 Discontinued Products 39
7.1 Onychomycosis (Tinea Unguium) 39
8 Product Development Milestones 40
8.1 Onychomycosis (Tinea Unguium) 40
8.2 Tinea pedis (Athlete Foot) 50

2018 Increasing Demand for Cognitive Impairment Disorders Drug Development Pipeline Review

Researchmoz added Most up-to-date research on "2018 Increasing Demand for Cognitive Impairment Disorders Drug Development Pipeline Review" to its huge collection of research reports.

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Scope

- Which companies are the most active within the pipeline for cognitive impairment disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1743272

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse TOC @ https://www.researchmoz.us/cognitive-impairment-disorders-drug-development-pipeline-review-2018-report.html/toc

Table Of Content

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 12
2.1 Cognitive Impairment Disorders Report Coverage 12
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12
2.3 Dementia - Overview 12
2.4 Mild Cognitive Impairment - Overview 12
2.5 Alzheimer's Disease - Overview 12
3 Therapeutics Development 13
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13
3.2 Dementia 18
3.3 Mild Cognitive Impairment 30
3.4 Alzheimer's Disease 36
4 Therapeutics Assessment 90
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90
4.2 Dementia 97
4.3 Mild Cognitive Impairment 108

New Survey Reveals: Diarrhea and Constipation Drug Development Pipeline Review, 2018

Researchmoz added Most up-to-date research on "New Survey Reveals: Diarrhea and Constipation Drug Development Pipeline Review, 2018" to its huge collection of research reports.

This report provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877888

The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.

Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.

Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/diarrhea-and-constipation-drug-development-pipeline-review-2018-report.html/toc

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Detailed Overview Of Respiratory Tract Infections Drug Development Pipeline Review, 2018

Researchmoz added Most up-to-date research on "Detailed Overview Of Respiratory Tract Infections Drug Development Pipeline Review, 2018" to its huge collection of research reports.

This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877889

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/respiratory-tract-infections-drug-development-pipeline-review-2018-report.html/toc

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

In Depth Research: Blood Pressure Disorders Drug Development Pipeline Review, 2018

Researchmoz added Most up-to-date research on "In Depth Research: Blood Pressure Disorders Drug Development Pipeline Review, 2018" to its huge collection of research reports.

This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels.

Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1894422

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.

Scope

• Which companies are the most active within the pipeline for blood pressure disorders?
• Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse TOC @ https://www.researchmoz.us/blood-pressure-disorders-drug-development-pipeline-review-2018-report.html/toc

Increasing Need Of Pancreatic and Bile Duct Cancer Drug Development: Size, Trends & Forecasts 2018

Researchmoz added Most up-to-date research on "Increasing Need Of Pancreatic and Bile Duct Cancer Drug Development: Size, Trends & Forecasts 2018" to its huge collection of research reports.

This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots.

Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1894423

Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca.

Scope

• Which companies are the most active within the pipeline for pancreatic and bile duct cancer?
• Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened within this field?

Browse TOC @ https://www.researchmoz.us/pancreatic-and-bile-duct-cancer-drug-development-pipeline-review-2018-report.html/toc

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Sickle Cell Disease Drug Development: Industry Size, Trends, Market Outlines, Assesses the Key Opportunities & Forecasts, 2017

Researchmoz added Most up-to-date research on "Sickle Cell Disease Drug Development: Industry Size, Trends, Market Outlines, Assesses the Key Opportunities & Forecasts, 2017" to its huge collection of research reports.

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. There are a total of 62 products in development for this indication, by 45 companies and nine academic institutions. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394151

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse TOC @ https://www.researchmoz.us/sickle-cell-disease-drug-development-pipeline-review-2017-report.html/toc

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sickle Cell Disease Report Coverage 7
2.2 Sickle Cell Disease Overview 7
2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview 7
3 Therapeutics Development 8
3.1 Sickle Cell Disease 8
3.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 15
4 Therapeutics Assessment 18
4.1 Sickle Cell Disease 18
4.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 25
5 Companies Involved in Therapeutics Development 31
5.1 Sickle Cell Disease 31
5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 47
6 Dormant Projects 52
6.1 Sickle Cell Disease 52
6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 54
7 Discontinued Products 55
7.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 55
8 Product Development Milestones 56

Advances in Hepatitis Drug Development For 2017: An Industrial Update

Researchmoz added Most up-to-date research on "Advances in Hepatitis Drug Development For 2017: An Industrial Update" to its huge collection of research reports.

This report provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.

Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis typically include dialysis, organ transplant and blood transfusion and the offspring of an infected mother also has high chances of contracting the disease.

Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; the size of these pipelines ranges from seven products in hepatitis A to 182 in hepatitis B and 199 in hepatitis C. Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both. While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.

Scope
- Which companies are the most active within the pipeline for hepatitis therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of hepatitis?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1277496

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 11
Introduction 12
Hepatitis Report Coverage 12
Hepatitis A - Overview 12
Hepatitis B - Overview 12
Hepatitis C - Overview 12
Hepatitis D - Overview 12
Therapeutics Development 13
Hepatitis A 13
Hepatitis B 17
Hepatitis C 30
Hepatitis D 43

Browse More Details @ http://www.researchmoz.us/hepatitis-drug-development-pipeline-review-2017-report.html